{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000008","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.685077+00:00","generated_at":"2026-05-26T03:02:56.670586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ligand Q4 revenue up 52% to $42.8M; core adj EPS $1.27; reaffirms 2025 guidance","bullets":["Q4 total rev $42.8M (+52% YoY); royalties $34.8M (+55%) driven by Qarziba and Filspari.","Core adjusted net income from cont ops $25.2M ($1.27/diluted) vs $18.6M ($1.05) prior year.","Full year adj net income $156.0M ($8.25/diluted); core adj $108.5M ($5.74/diluted).","Reaffirms 2025 guidance: total rev $180-200M, adjusted EPS $6.00-$6.25.","Closed $50M royalty investment in Castle Creek Biosciences for D-Fi Phase 3 study."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000008","json":"https://secwatch.observer/filing/0000886163-25-000008.json","markdown":"https://secwatch.observer/filing/0000886163-25-000008.md","text":"https://secwatch.observer/filing/0000886163-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/0000886163-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/lgnd-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:02:56.670586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}